Previously, in a mouse model of intestinal cancer, sunitinib administration at a dosing protocol of 30 mg/kg every other day for 9 weeks resulted in a reduction in various inflammation-related factors, such as IL-6, IL-1α/1β, TNFα, and IFN-γ at the mRNA level within the GI tract [51]. This evidence concerns the gene IFNG and intestinal cancer.